Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company's annual meeting of stockholders, which is anticipated to be held in June 2026. Ms. Yarno will continue to serve as a director until the annual meeting. The company stated that her decision to retire is not due to any disagreement with Iovance regarding its operations, policies, or practices, and publicly thanked her for her service on the Board. 03/20/2026 - 05:00 PM Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): (Exact Name of Registrant as Specified in Charter) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Securities registered pursuant to Section 12(b) of the Act: On March 17, 2026, Wendy Yarno, a member of the Board of Directors (the "") of Iovance Biotherapeutics, Inc. (the ""), provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company's annual meeting of stockholders (the "") currently anticipated to be held in June 2026. Ms. Yarno will serve out her current term as a director of the Company until the Annual Meeting. The decision to retire and not stand for re-election is not due to a disagreement between the Company and Ms. Yarno on any matter regarding the Company's operations, policies, or practices. The Company thanks Ms. Yarno for her service to the Board. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Faq. What board change did Iovance Biotherapeutics (IOVA) disclose in this 8-K? Iovance Biotherapeutics disclosed that board member Wendy Yarno will retire and not stand for re-election at the upcoming annual meeting. She will remain on the Board until that meeting, and the company expressed appreciation for her service and contributions. When will Iovance Biotherapeutics (IOVA) director Wendy Yarno retire from the Board? Wendy Yarno will retire from the Iovance Biotherapeutics Board at the company's annual meeting of stockholders, currently anticipated for June 2026. She will continue serving as a director until that meeting, providing continuity during the transition period for the Board. Did Wendy Yarno's retirement from Iovance Biotherapeutics (IOVA) involve any disagreement with the company? The company stated that Wendy Yarno's decision to retire and not stand for re-election was not due to any disagreement regarding Iovance's operations, policies, or practices. This language signals an orderly governance transition rather than a dispute-driven departure. What role did Wendy Yarno hold at Iovance Biotherapeutics (IOVA) before announcing retirement? Wendy Yarno served as a member of the Board of Directors of Iovance Biotherapeutics. She notified the Board on March 17, 2026 that she will retire and not stand for re-election at the company's anticipated June 2026 annual stockholder meeting. How did Iovance Biotherapeutics (IOVA) characterize Wendy Yarno's retirement from the Board? Iovance Biotherapeutics indicated that Wendy Yarno's retirement is a personal decision, explicitly noting no disagreement over operations, policies, or practices. The company publicly thanked her for her service, framing the change as a normal board succession event. Filing exhibits & attachments. 3 documents

Iovance Biotherapeutics reached a new 52-week high of $5.34 on Friday before closing at $5.13, up 12.01 per cent, following UBS doubling its price target to $4 from $2, though maintaining a neutral rating. Wells Fargo reaffirmed its buy recommendation with a $14 price target. The biopharmaceutical company will participate in Barclays' 28th Annual Global Healthcare Conference on 11 March, where investors will watch for business updates. Iovance reported a 5 per cent wider net loss for 2024 at $390.98 million, whilst total revenues jumped 60.6 per cent to $263.5 million. Fourth-quarter net loss narrowed 8 per cent to $71.9 million, with revenues increasing 17.6 per cent to $86.7 million year-on-year.